抗PD-L1治疗预防大鼠多发性创伤性脑损伤后全身免疫抑制
本研究为幼年大鼠基础科学实验,探讨抗PD-L1抗体能否安全预防多发性创伤性脑损伤(TBI+全身出血)后的免疫抑制。大鼠接受TBI+出血或假手术后,每日注射生理盐水或抗PD-L1(10 μg或100 μg)共7天,通过全血和脾细胞脂多糖刺激后TNFα反应评估免疫功能。结果显示TBI+出血导致全血和脾脏TNFα反应降低(p=0.02),仅100 μg抗PD-L1可提高全血(p=0.04)和脾脏(p=0.02)TNFα反应,低剂量无效;但100 μg组损伤周围小胶质细胞(p=0.004)和星形胶质细胞(p=0.03)增多,且Barnes迷宫表现更差(p=0.007)。作者结论认为PD-L1阻断可能不是儿童TBI后安全逆转免疫抑制的良好候选方案。
要点
- 幼年大鼠TBI+全身出血后全血和脾脏TNFα反应较假手术组降低(p=0.02),提示全身免疫抑制。
- 仅100 μg抗PD-L1(每日注射共7天)可提高TBI+出血大鼠全血(p=0.04)和脾脏(p=0.02)TNFα反应,10 μg剂量无效。
- 100 μg抗PD-L1组损伤周围小胶质细胞计数(p=0.004)和星形胶质细胞计数(p=0.03)均高于TBI+出血+生理盐水组。
- 10 μg抗PD-L1组Barnes迷宫结果与假手术组无差异,但100 μg组空间记忆表现更差(p=0.007)。
- 作者认为PD-L1阻断可能不是儿童TBI后安全逆转免疫抑制的良好候选方案。
适用人群与场景
- 幼年大鼠多发性创伤性脑损伤模型(TBI+全身出血),以及假手术对照。
处置流程与药物剂量
- TBI+出血或假手术后,每日注射生理盐水或抗PD-L1(10 μg或100 μg),共7天。
- 通过全血和脾细胞体外脂多糖刺激后TNFα产生评估全身免疫功能,细胞因子用ELISA或蛋白组阵列检测。
- 用免疫荧光定量伤后第7天脑组织中小胶质细胞、星形胶质细胞和神经元。
- 伤后第1天通过行为学测试评估认知功能。
研究设计与关键结果
- 研究类型:基础科学/动物实验,幼年大鼠TBI+全身出血模型。
- TBI+出血导致全血和脾脏TNFα反应低于假手术组(p=0.02)。
- 100 μg抗PD-L1组全血TNFα反应高于TBI+出血+生理盐水组(p=0.04),脾脏TNFα反应也高于TBI+出血+生理盐水组(p=0.02);10 μg抗PD-L1对免疫功能无影响。
- 未刺激血浆蛋白组阵列显示,伤后第7天100 μg抗PD-L1组炎症介质水平高于生理盐水组。
- 100 μg抗PD-L1组损伤周围小胶质细胞计数(p=0.004)和星形胶质细胞计数(p=0.03)均高于TBI+出血+生理盐水组。
- Barnes迷宫结果:10 μg抗PD-L1组与假手术组无差异,100 μg组表现更差(p=0.007)。
证据类型、等级与局限
- 证据类型:基础科学/动物研究;证据等级:不适用(Not applicable)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为PD-L1阻断可能不是儿童TBI后安全逆转免疫抑制的良好候选方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Trauma is a leading cause of pediatric morbidity and mortality. Children with traumatic brain injury (TBI), especially with extracranial injuries, can develop immune suppression and subsequent infection. Immune checkpoint pathways, for example, programmed death-ligand 1 (PD-L1), may contribute. We hypothesized that an anti-PD-L1 antibody would safely prevent immune suppression in a juvenile rat model of polytraumatic TBI.
METHODS: Juvenile rats underwent TBI plus systemic hemorrhage (TBI/H) or sham injury. Rats received daily injections of saline or anti-PD-L1 (10 μg or 100 μg) for 7 days. Systemic immune function was assessed by measuring TNFα production in whole blood and splenocytes after ex vivo stimulation with lipopolysaccharide. Cytokines were measured by ELISA or proteome array. Immunofluorescence was used to quantify microglia, astrocytes, and neurons in postinjury day (PID) 7 brain tissue. Cognitive function was assessed by behavioral testing on PID 1.
RESULTS: TBI/H resulted in lower TNFα response in whole blood and spleen ( p =0.02) versus sham-injured rats. TBI/H rats treated with 100 μg anti-PD-L1 had higher TNFα response in whole blood ( p =0.04) and spleen ( p =0.02) versus TBI/H rats treated with saline. Lower dose anti-PD-L1 had no effect on immune function. Unstimulated plasma was examined using a proteome array, and higher levels of inflammatory mediators were noted on PID 7 in injured animals treated with 100 µg anti-PD-L1 versus saline. The 100 μg anti-PD-L1 group had higher perilesional microglia ( p =0.004) and astrocyte ( p =0.03) counts, as compared with TBI/H+saline. Barnes maze results were not different between injured rats treated with 10 μg anti-PD-L1 versus sham injury, but the 100 μg dose resulted in worse performance ( p =0.007).
CONCLUSIONS: Anti-PD-L1 treatment prevented posttraumatic immune suppression but only at a dose that resulted in higher numbers of perilesional microglia and no improvement in spatial memory. As such, PD-L1 blockade may not be a good candidate for safely reversing immune suppression after pediatric TBI. ( J Trauma Acute Care Surg. 2026;00:00-00. Copyright © 2026 The Author(s). Published byWolters Kluwer Health, Inc. on behalf of the American Association for the Surgery of Trauma.).
LEVEL OF EVIDENCE: Not applicable (basic science/animal research).
参考来源
- Bahader GA, Fimbres JC, Blum SD, et al. Anti-PD-L1 therapy to prevent systemic immune suppression after polytraumatic brain injury in rats. J Trauma Acute Care Surg. 2026. PMID: 41870894. doi:10.1097/TA.0000000000004935
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。